A substantial number of anticancer drugs receive marketing authorization on the basis of data that do not prove their superiority over standard-of-care treatment because of the use of substandard control arms in clinical trials. Use of a substandard control arm exaggerates the clinical benefit of the experimental agent and can mislead physicians, patients, and regulatory and health technology assessment bodies.